Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Acurx Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PIONEERING DATA DEMONSTRATE THATACURX'S U.S. AND EU PHASE 3-READY DNA POL IIIC INHIBITOR, IBEZAPOLSTAT (IBZ), HAS UNIQUE SELECTIVE ANTIBACTERIAL ACTIVITY IN THE GUT WHICH SPARES BENEFICIAL BILE ACID-METABOLIZING BACTERIA THE FAVORABLE GUT BILE ACID PROFILE CONTRIBUTES TOIBEZAPOLSTAT'SANTI-RECURRENCEEFFECTINPATIENTSWITHC.DIFFICILEINFECTION(CDI) NEW DATA PRESENTED ON REPRESENTATIVE NOVEL COMPOUNDS FROMACURX'S DNA POL IIIC INHIBITOR PRECLINICAL PIPELINE PROVIDE INITIAL EVIDENCE THAT MICROBIOME SELECTIVITY, WHEN COMPARED TO THE COMPARATOR ANTIBIOTIC, LINEZOLID, MAY BE A CLASS EFFECT IBEZAPOLSTAT HAS PREVIOUSLY RECEIVED FDA QIDP AND FAST-TRACK DESIGNATION FROM FDA; ACURX'S PRECLINICAL ANTIBIOTIC CANDIDATES ARE FDA QIDP/FAST TRACK ELIGIBLE FOR SYSTEMIC TREATMENT OF INFECTIONS CAUSED BY OTHER GRAM-POSITIVE PRIORITY PATHOGENS STATEN ISLAND, N.Y.

ACURX ANNOUNCES NEW DATA ON ITS DNA POL IIIC INHIBITOR ANTIBIOTICS DEMONSTRATING A POTENTIAL CLASS EFFECT OF GUT MICROBIOME SELECTIVITY PRESENTED AT IDWEEK 2025 SCIENTIFIC CONFERENCE

STATEN ISLAND, N.Y. , OCT. 27, 2025 /PRNEWSWIRE/ -- ACURX PHARMACEUTICALS, INC. (NASDAQ: ACXP) ("ACURX" OR THE "COMPANY"), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING A NEW CLASS OF ANTIBIOTICS FOR DIFFICULT-TO-TREAT BACTERIAL INFECTIONS, ANNOUNCED TODAY THAT THE COMPANY WILL DISCUSS ITS THIRD QUARTER 2025 FINANCIAL RESULTS ON WEDNESDAY, NOVEMBER 12, 2025 AT 8:00 AM ET BEFORE THE U.S. FINANCIAL MARKETS OPEN.

ACURX PHARMACEUTICALS TO DISCUSS THIRD QUARTER 2025 FINANCIAL RESULTS ON NOVEMBER 12, 2025 CONFERENCE CALL AND PROVIDE BUSINESS UPDATE

STATEN ISLAND, N.Y. , OCT. 9, 2025 /PRNEWSWIRE/ --ACURX PHARMACEUTICALS, INC. (NASDAQ: ACXP) ("ACURX" OR THE "COMPANY"), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPINGANEWCLASS OFSMALLMOLECULE ANTIBIOTICSFORDIFFICULT-TO-TREATBACTERIALINFECTIONS, TODAY ANNOUNCED THAT A NEW PATENT HAS BEEN GRANTED BY THE AUSTRALIAN PATENT OFFICE.

AUSTRALIAN PATENT OFFICE GRANTS ACURX PATENT FOR DNA POLYMERASE IIIC INHIBITORS

STATEN ISLAND, N.Y. , AUG. 12, 2025 /PRNEWSWIRE/ --ACURX PHARMACEUTICALS, INC. (NASDAQ: ACXP) ("ACURX" OR THE "COMPANY"), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING A NEW CLASS OF ANTIBIOTICS FOR DIFFICULT-TO-TREAT BACTERIAL INFECTIONS, ANNOUNCED TODAY CERTAIN FINANCIAL AND OPERATIONAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025.

ACURX PHARMACEUTICALS, INC. REPORTS SECOND QUARTER RESULTS AND PROVIDES BUSINESS UPDATE

ACURX'S COMMON STOCK IS EXPECTED TO BEGIN TRADING ON A POST-SPLIT ADJUSTED BASIS ON AUGUST 5, 2025 STATEN ISLAND, N.Y. , JULY 31, 2025 /PRNEWSWIRE/ -- ACURX PHARMACEUTICALS, INC. (NASDAQ: ACXP) ("ACURX" OR THE "COMPANY"), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING A NEW CLASS OF ANTIBIOTICS FOR DIFFICULT-TO-TREAT BACTERIAL INFECTIONS, TODAY ANNOUNCED THAT THE BOARD OF DIRECTORS OF THE COMPANY APPROVED A1-FOR-20 REVERSE STOCK SPLIT (THE "REVERSE SPLIT") OF THE COMPANY'S COMMON STOCK.

ACURX PHARMACEUTICALS, INC. ANNOUNCES REVERSE STOCK SPLIT

STATEN ISLAND, N.Y. , JULY 24, 2025 /PRNEWSWIRE/ -- ACURX PHARMACEUTICALS, INC. (NASDAQ: ACXP) ("ACURX" OR THE "COMPANY"), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING A NEW CLASS OF ANTIBIOTICS FOR DIFFICULT-TO-TREAT BACTERIAL INFECTIONS, ANNOUNCED TODAY THAT THE COMPANY WILL DISCUSS ITS SECOND QUARTER 2025 FINANCIAL RESULTS ON TUESDAY, AUGUST 12, 2025 AT 8:00 AM ET BEFORE THE U.S. FINANCIAL MARKETS OPEN.

ACURX PHARMACEUTICALS TO DISCUSS SECOND QUARTER 2025 FINANCIAL RESULTS ON AUGUST 12, 2025 CONFERENCE CALL AND PROVIDE BUSINESS UPDATE

STATEN ISLAND, N.Y. , JUNE 17, 2025 /PRNEWSWIRE/ -- ACURX PHARMACEUTICALS, INC. (NASDAQ: ACXP) ("ACURX" OR THE "COMPANY"), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING A NEW CLASS OF ANTIBIOTICS FOR DIFFICULT-TO-TREAT BACTERIAL INFECTIONS, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A WARRANT INDUCEMENT AGREEMENT (THE "LETTER AGREEMENT") WITH A CERTAIN HOLDER ("HOLDER") OF EXISTING WARRANTS TO PURCHASE UP TO AN AGGREGATE OF 4,445,435 SHARES OF COMMON STOCK (THE "EXISTING WARRANTS") HAVING EXERCISE PRICES RANGING FROM $3.25 TO $3.26 PER SHARE, ISSUED BY THE COMPANY IN JULY 2022 AND MAY 2023, WHEREIN THE HOLDER AGREED TO EXERCISE THE EXISTING WARRANTS AT A REDUCED EXERCISE PRICE OF $0.675 PER SHARE, RESULTING IN GROSS PROCEEDS OF APPROXIMATELY $2.67 MILLION, BEFORE DEDUCTING OFFERING FEES AND OTHER EXPENSES PAYABLE BY THE COMPANY.

ACURX PHARMACEUTICALS, INC. ANNOUNCES EXERCISE OF WARRANTS FOR $2.67 MILLION GROSS PROCEEDS

AS PREVIOUSLY REPORTED, 15 OUT OF 16 (94%) PATIENTS IN PHASE 2B IN THE PER PROTOCOL POPULATION EXPERIENCED CLINICAL CURE (CC) AND ALL 15 OF 15 (100%) REMAINED FREE OFC. DIFFICILEINFECTION (CDI) RECURRENCE THROUGH ONE MONTH AFTER EOT IN CONTRAST, 2 OF 14 (14%) PATIENTS TREATED WITH THE STANDARD OF CARE, ORALVANCOMYCIN, EXPERIENCED RECURRENT INFECTION WITHIN ONE MONTH AFTER EOT WHEN PHASE 2B RESULTS ARE COMBINED WITH PHASE 2A RESULTS, 25 OF 25 (100%)IBEZAPOLSTAT-TREATED PATIENTS WITH CDI WHO HAD CC AT EOT REMAINED RECURRENCE-FREE THROUGH 1 MONTH AFTER EOT; ADDITIONALLY, ALL 5 PHASE 2B IBEZAPOLSTAT-TREATED PATIENTS OBSERVED FOR UP TO 3 MONTHS FOLLOWING CC EXPERIENCED NO RECURRENCE OF INFECTION ADDING TO THIS LANCET MICROBE PUBLICATION, TWO RECENT JOURNAL OF ANTIMICROBIAL AGENTS AND CHEMOTHERAPEUTICS PUBLICATIONS REGARDING, RESPECTIVELY, FAVORABLE GUTMICROBIOME EFFECTS WHICH DIFFERENTIATE IBZ FROM OTHER ANTI-CDI ANTIBIOTICS AND POSITIVE RESULTS FROM AN IN-SILICO STUDY PREDICTING THE MICROBIOME-RESTORATIVE POTENTIAL OF IBZ THE TOTALITY OFIBEZAPOLSTAT DATA-TO-DATE FURTHER ADVANCES ACURX'S ROBUST DATA PACKAGE AND ARE RESHAPING THE THERAPEUTIC LANDSCAPE FOR FUTURE TREATMENT OF CDI WITH IBEZAPOLSTAT'S INNOVATIVE AND POTENTIALLY TRANSFORMATIVE NEW CLASS OF ANTIBIOTICS TO TREAT GRAM-POSITIVE INFECTIONS WHILE PRESERVING AND RESTORING THE PROTECTIVE GUT MICROBIOTA ACURX IS WELLPOSITIONED TO BEGIN INTERNATIONAL PHASE 3 CLINICAL TRIALS AND HAS PREVIOUSLY BEEN GRANTED FDA QIDP AND FAST-TRACK DESIGNATION AND HAS RECEIVED SME (SMALL AND MEDIUM-SIZED ENTERPRISE) DESIGNATION BY THE EMA STATEN ISLAND,N.Y.

ACURX ANNOUNCES PUBLICATION IN LANCET MICROBE OF PHASE 2B CLINICAL TRIAL DATA FOR IBEZAPOLSTAT IN CDI

RESULTS ARE FROM ACURX'S ONGOING SCIENTIFIC COLLABORATION WITH LEIDEN UNIVERSITY MEDICAL CENTER (LUMC) PARTIALLY UNDER A GRANT FROM HEALTH HOLLAND TO FURTHER STUDY THE MECHANISM OF ACTION OF DNA POL IIIC INHIBITORS LUMC HIGHLIGHTED ACURX'S NEW CLASS OF PROMISING ANTIMICROBIALS, IBEZAPOLSTAT AND RELATED ANALOGUES NOVEL CHEMOTYPE SPECIFICALLY TARGETING GRAM-POSITIVE BACTERIA THROUGH AN UNEXPLOITED TARGET IBEZAPOLSTAT READY TO ENTER PIVOTAL PHASE 3 CLINICAL TRIALS FOR C. DIFFICILE INFECTION (CDI), WITH NO CROSS RESISTANCE REPORTED TO DATE IBEZAPOLSTAT HAS PREVIOUSLY BEEN GRANTED FDA QIDP AND FAST-TRACK DESIGNATIONS AND HAS RECEIVED SME (SMALL AND MEDIUM-SIZED ENTERPRISE) DESIGNATION BY THE EMA STATEN ISLAND,N.Y.

ACURX PHARMACEUTICALS ANNOUNCES PRESENTATION OF RESULTS FROM LEIDEN UNIVERSITY MEDICAL CENTER PUBLIC-PRIVATE PARTNERSHIP FOR ITS DNA POL IIIC INHIBITORS AT THE FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY SCIENTIFIC CONFERENCE

STATEN ISLAND, N.Y. , MAY 13, 2025 /PRNEWSWIRE/ --ACURX PHARMACEUTICALS, INC. (NASDAQ: ACXP) ("ACURX" OR THE "COMPANY"), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING A NEW CLASS OF ANTIBIOTICS FOR DIFFICULT-TO-TREAT BACTERIAL INFECTIONS, ANNOUNCED TODAY CERTAIN FINANCIAL AND OPERATIONAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025.

Acurx Pharmaceuticals, Inc.

ACXP

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Acurx Pharmaceuticals, Inc.

ACXP.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ACXP